Julie Steelandt1, Elodie Jean-Bart1, Sylvain Goutelle2,3, Michel Tod4,5. 1. Pharmacie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France. 2. Pharmacie, Hôpital Pierre Garaud, Hospices Civils de Lyon, Lyon, France. 3. UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, Villeurbanne, France. 4. Pharmacie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69004, Lyon, France. michel.tod@univ-lyon1.fr. 5. Département de Physiologie, Pharmacologie, Toxicologie, Faculté de Pharmacie, Université Lyon 1, Lyon, France. michel.tod@univ-lyon1.fr.
Abstract
BACKGROUND AND OBJECTIVE: Prediction of drug clearance in liver cirrhosis patients is currently based on in vitro-in vivo extrapolation and physiologically-based pharmacokinetic models. No static model for this purpose has been described. The objectives of this study were to (1) derive a static model for predicting drug exposure in cirrhotic patients, and (2) to evaluate the model on a large set of published data. METHODS: The impact of cirrhosis was characterized by the ratio of the total and unbound drug area under the concentration-time curve (AUC) in cirrhotic patients to the AUC measured in healthy subjects These ratios were predicted for Child-Pugh classes A, B, and C. The AUC ratios observed in published data were compared with AUC ratios predicted by the model. RESULTS: Among 171 drugs examined, 83 published AUC ratios for 45 drugs in cirrhotic patients were available for analysis. The mean ± standard deviation relative prediction error for the total and unbound AUC ratios was 0.22 ± 0.58 and 0.24 ± 0.56, respectively. There were four outliers among the 83 predicted values. Simulations showed that the prediction error was negligible provided that the hepatic extraction coefficient was less than 0.8. CONCLUSIONS: For mild and moderate cirrhosis (classes A and B), the predicted unbound AUC ratio is typically approximately 2 and 3.5, respectively, for most drugs. In the absence of data in cirrhotic patients, the drug dose might be empirically reduced by these factors. In severe cirrhosis (class C), our model may help clinicians to adjust their prescriptions.
BACKGROUND AND OBJECTIVE: Prediction of drug clearance in liver cirrhosispatients is currently based on in vitro-in vivo extrapolation and physiologically-based pharmacokinetic models. No static model for this purpose has been described. The objectives of this study were to (1) derive a static model for predicting drug exposure in cirrhotic patients, and (2) to evaluate the model on a large set of published data. METHODS: The impact of cirrhosis was characterized by the ratio of the total and unbound drug area under the concentration-time curve (AUC) in cirrhotic patients to the AUC measured in healthy subjects These ratios were predicted for Child-Pugh classes A, B, and C. The AUC ratios observed in published data were compared with AUC ratios predicted by the model. RESULTS: Among 171 drugs examined, 83 published AUC ratios for 45 drugs in cirrhotic patients were available for analysis. The mean ± standard deviation relative prediction error for the total and unbound AUC ratios was 0.22 ± 0.58 and 0.24 ± 0.56, respectively. There were four outliers among the 83 predicted values. Simulations showed that the prediction error was negligible provided that the hepatic extraction coefficient was less than 0.8. CONCLUSIONS: For mild and moderate cirrhosis (classes A and B), the predicted unbound AUC ratio is typically approximately 2 and 3.5, respectively, for most drugs. In the absence of data in cirrhotic patients, the drug dose might be empirically reduced by these factors. In severe cirrhosis (class C), our model may help clinicians to adjust their prescriptions.
Authors: Jürgen Brockmöller; Torben Thomsen; Marcus Wittstock; René Coupez; Herbert Lochs; Ivar Roots Journal: Clin Pharmacol Ther Date: 2005-06 Impact factor: 6.875
Authors: Monika Schöller-Gyüre; Thomas N Kakuda; Goedele De Smedt; Brian Woodfall; Cindy Berckmans; Monika Peeters; Richard M W Hoetelmans Journal: Clin Ther Date: 2010-02 Impact factor: 3.393
Authors: Albader Albarmawi; David Czock; Annika Gauss; Robert Ehehalt; Justo Lorenzo Bermejo; Jürgen Burhenne; Tom M Ganten; Peter Sauer; Walter E Haefeli Journal: Br J Clin Pharmacol Date: 2014-01 Impact factor: 4.335
Authors: Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; Nicole G M Hunfeld; Minke Kranenborg; Margje H Monster-Simons; Sandra A W van Putten; Herold J Metselaar; Katja Taxis; Sander D Borgsteede Journal: BMJ Open Date: 2016-10-12 Impact factor: 2.692
Authors: Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; S Froukje Harkes-Idzinga; Nicole G M Hunfeld; Herold J Metselaar; Margje H Monster-Simons; Sandra A W van Putten; Katja Taxis; Sander D Borgsteede Journal: Br J Clin Pharmacol Date: 2018-06-07 Impact factor: 4.335
Authors: Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; S Froukje Harkes-Idzinga; Nicole G M Hunfeld; Herold J Metselaar; Margje H Monster-Simons; Katja Taxis; Sander D Borgsteede Journal: Drug Saf Date: 2018-06 Impact factor: 5.606